Sign up
Pharma Capital

Silence Therapeutics pleased with pipeline progress of Quark Pharma

Quark has dosed the first patient in a phase III trial of its QPI-1002 drug which uses Silence’s chemical modification technology
scientist with a microscope
If the drug is a success, Silence stands to receive royalties from Quark

An Israeli pharma group which has licensed Silence Therapeutics PLC's (LON:SLN) chemical modification technology has dosed the first patient in a phase III trial of its acute kidney injury treatment.

Quark Pharmaceuticals also announced it has reached an agreement with the US Food and Drug Administration on the overall study design with a new primary endpoint.

Silence is eligible to receive either approximately 1.5%-4% royalties from Quark on the QPI-1002 drug plus milestones, or 15% of the clinical, regulatory and commercial milestone payments and royalties received by Quark from its partner Novartis.

“We are pleased to see the pipeline progress made by Quark Pharmaceuticals,” said Silence executive chair Annalisa Jenkins.

“Based upon positive data observed in their phase II programme, Quark have successfully transitioned to a major pivotal phase III programme for patients at high risk post cardiac surgery requiring prevention of Acute Kidney Injury (AKI).

“This significant global siRNA programme includes proprietary chemical modification technology developed by Silence Therapeutics.”

View full SLN profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.